Brit J Heamatol: Primary prevention of venous thromboembolism in patients with multiple myeloma treated with immunomodulators
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Immunomodulation drugs (IMiDs) improve survival in patients with multiple myeloma (MM) and are the cornerstone of treatment at all stagesDespite good tolerance, IMiD can increase the incidence of venous thromboembolism (VTE)recently published a study in the journal British Journal of Haematology, an authoritative journal of blood system diseases, in which 50 MM patients treated with IMID were given 2.5 mg oral apixaban spent twice a day to prevent VTE and undergo six months of forward-looking monitoringThe main safety outcome of the study was the incidence of haemorrhage and clinically related incidence of non-hemorrhage within six monthsThe main therapeutic outcome of the study was the incidence of symptomatic VTE within six monthsThe iMiD used by the subjects was either penadomine (58%) or pomalidomide (42%)no patients developed haemorrhage or VTE during the six-month evaluation periodThree patients experienced clinically related non-large bleeding and all were able to retake apixabanOne patient stopped treatment shortly after starting treatment because of an allergy to apixabanNo patients have a stroke, myocardial infarction or deathin this prospective study, low-dose apixaban is safe and well tolerated as a Primary Prevention Strategy for MM patients treated with IMiDFurther research is needed to verify whether low-dose apixaban can be used as a standard primary prevention strategy for antithrombotic in MM patients treated with IMiD
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
